Semaglutide Linked to Reduced Asthma Attacks and COPD Flare-Ups in New Study
Semaglutide, originally introduced for its benefits in managing diabetes and aiding weight loss, has recently been the subject of new research that uncovers additional health benefits unrelated to weight. A study presented at the 2026 European Respiratory Society (ERS) Congress revealed that individuals with asthma or chronic obstructive pulmonary disease (COPD) who were prescribed semaglutide experienced fewer acute respiratory attacks compared to those taking other diabetes medications. The research utilized UK electronic medical records to conduct four parallel studies, each involving between 20,000 and 22,000 participants who had begun treatment with either a GLP-1 medication like semaglutide or sulfonylureas, another class of diabetes drugs. The results showed that patients with asthma taking semaglutide had a remarkable 40% reduction in asthma attacks, while those with COPD experienced a 20% decrease in flare-ups. This study is significant as it draws from real-world prescribing data rather than a controlled clinical trial, providing strong evidence of a correlation, though it cannot definitively establish causation. GLP-1 treatments are already well-known for their roles in managing type 2 diabetes and obesity, but researchers have long theorized that their effects might extend beyond metabolic health to include anti-inflammatory properties that could benefit lung health. Historically, asthma and COPD outcomes have not been tracked in GLP-1 drug trials, making this one of the largest studies to explore the relationship between these medications and respiratory diseases. The findings underscore the interconnectedness of obesity, metabolic dysfunction, and airway diseases, which are often treated separately in clinical practice. While the researchers do not advocate for the use of semaglutide solely for respiratory issues, they suggest that individuals managing both asthma or COPD and weight or blood sugar concerns should discuss these overlapping health issues with their healthcare providers. The study highlights the need for more research to fully understand the impact of GLP-1 drugs on respiratory health, but it serves as an important reminder of the broader health implications of medications initially designed for metabolic conditions.




